7 unchanged sentences
Performance Graph
−Removed: The graph below compares the cumulative total stockholders return on our common stock for the last five fiscal years with the cumulative total return on the Nasdaq Composite Index and the Russell 2000 Growth Biotechnology Index (which includes Novavax) over the same period, assuming the investment of $100 in our common stock, the Nasdaq Composite Index and the Russell 2000 Growth Biotechnology Index on December 31, 2015, and reinvestments of all dividends.
+Added: The graph below matches Novavax, Inc.'s cumulative 5-Year total shareholder return on common stock with the cumulative total returns of the Nasdaq Composite Index and the Russell 2000 Growth Biotechnology Index.
+Added: The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from December 31, 2016 to December 31, 2021.
COMPARISON OF 5 YEAR CUMULATIVE RETURN*
3 unchanged sentences
Fiscal year ending December 31.
−Removed: Table of C onten ts
Value of $100 invested on December 31, 2016 in stock or index, including reinvestment of dividends, for fiscal years ended December 31:
5 unchanged sentences
This graph is not “soliciting material,” is not deemed “filed” with the SEC, and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
−Removed: SELECTED FINANCIAL DATA
−Removed: The following table sets forth selected financial data for each of the years in the five-year period ended December 31, 2020, which have been derived from our audited consolidated financial statements.
−Removed: The information below should be read in conjunction with our consolidated financial statements and notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this Annual Report.
−Removed: These historical results are not necessarily indicative of results for future periods.
−Removed: Year Ended December 31,
−Removed: (in thousands, except per share amounts)
−Removed: Statements of Operations Data (5) :
−Removed: Revenue $ 475,598 $ 18,662 $ 34,288 $ 31,176 $ 15,353
−Removed: Net loss (418,259) (132,694) (184,748) (183,769) (279,966)
−Removed: Basic and diluted net loss per share (7.27) (5.51) (9.99) (12.56) (20.68)
−Removed: Weighted average shares used in computing basic and diluted net loss per share 57,554 24,100 18,488 14,633 13,540
−Removed: As of December 31,
−Removed: (in thousands)
−Removed: Balance Sheet Data:
−Removed: Cash and cash equivalents, marketable securities and restricted cash $ 806,387 $ 82,180 $ 103,939 $ 186,427 $ 270,383
−Removed: Total current assets 1,248,203 97,247 119,276 203,311 287,830
−Removed: Working capital(6) 668,531 71,452 73,737 129,636 221,424
−Removed: Total assets(7) 1,582,479 172,957 207,978 302,493 394,301
−Removed: Long-term debt 322,035 320,611 319,187 317,763 316,339
−Removed: Accumulated deficit (1,874,199) (1,431,801) (1,299,107) (1,114,359) (929,996)
−Removed: Total stockholders’ (deficit) equity 627,209 (186,017) (167,935) (101,732) (5,546)
−Removed: ______________________________
−Removed: (1) In 2020, we had sales of 32.4 million shares of common stock and we sold 0.4 million shares of preferred stock, which were converted to 4.4 million shares of common stock in the fourth quarter 2020, resulting in total net proceeds of approximately $1.1 billion.
−Removed: (2) In 2019, we had sales of 13.0 million shares of common stock resulting in net proceeds of approximately $98 million.
−Removed: (3) In 2018, we had sales of 2.9 million shares of common stock resulting in net proceeds of approximately $100 million.
−Removed: (4) In 2017, we had sales of 2.5 million shares of common stock resulting in net proceeds of approximately $63 million.
−Removed: Table of C onten ts
−Removed: (5) All share and per share amounts have been retroactively restated for all periods presented to reflect the Reverse Stock Split (see Note 12 to the accompanying consolidated financial statements).
−Removed: (6) Working capital is computed as the excess of current assets over current liabilities.
−Removed: (7) In 2019, the Company adopted ASU 20160-02, Leases (Topic 842), under which the Company recorded right-of-use assets associated with its leases on the consolidated balance sheet (see Note 7 to the accompanying consolidated financial statements).
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.